Please provide your email address to receive an email when new articles are posted on . Pembrolizumab plus axitinib continued to exhibit superior efficacy to sunitinib as first-line therapy for ...

Bottom Line: Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical ...

A study was conducted to compare cardiovascular outcomes for single-pill antihypertensive combination therapy and identical multiple pill therapy. Risk for CV events and all-cause mortality is ...

Please provide your email address to receive an email when new articles are posted on . Three strategies aimed at starting patients with polyarticular juvenile idiopathic arthritis on different ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...

49% of patients treated with Opdivo plus Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free Data to be featured in an oral presentation during the 2021 American Society ...

Derek van Amerongen, MD, MS: One of the important topics of discussion within a health plan, whenever we’re discussing treatment A versus treatment B, especially at the P&T discussions, is, what does ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, ...

Combination treatment with two PD-1 inhibitors — Yervoy and Opdivo — did not improve survival without cancer recurrence compared with Opdivo alone in patients with high-risk melanoma, a type of skin ...

ORLANDO, Fla.--The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients ...